title: Phase II trial of docetaxel in Asian patients with inoperable stage III non-small cell lung cancer.
abstract: Docetaxel has a response rate of greater than 30% in first-line treatment of Western patients with advanced non-small cell lung cancer (NSCLC). The goal of this open-label. phase II study was to evaluate the activity and safety profile of docetaxel in Asian patients with inoperable untreated stage III NSCLC. Docetaxel was given at 100 mg/m2 as a 1-h infusion every 3 weeks. Prophylactic dexamethasone was given to reduce hypersensitivity reactions and edema. Thirty-five patients were enrolled in the study. The response rate was 34% (95% CI, 19%-50%) according to intent-to-treat analysis. No complete response was observed. Twenty-four patients (69%) had grade 3 or 4 neutropenia in cycle 1, and febrile neutropenia was seen in 12 patients. Six patients (17%) experienced mild fluid retention. Docetaxel is an active agent in first-line treatment of Asian patients with locally advanced NSCLC, with the main toxicity being neutropenia. Fluid retention was a minor problem in this study.
authors.affiliation: Department of Medical Oncology, National University Hospital, Singapore. gohbc@pacific.net.sg
authors.forename: B C
authors.initials: BC
authors.lastname: Goh
authors.forename: M
authors.initials: M
authors.lastname: Lehnert
authors.forename: H L
authors.initials: HL
authors.lastname: Lim
authors.forename: A W
authors.initials: AW
authors.lastname: Ng
authors.forename: C C
authors.initials: CC
authors.lastname: Chan
authors.forename: H L
authors.initials: HL
authors.lastname: Kong
authors.forename: S C
authors.initials: SC
authors.lastname: Lee
authors.forename: J
authors.initials: J
authors.lastname: Wee
authors.forename: E T
authors.initials: ET
authors.lastname: Chua
authors.forename: J E
authors.initials: JE
authors.lastname: Wong
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000932:Antiemetics / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D003907:Dexamethasone / Q000008:administration & dosage; D000077143:Docetaxel; D005260:Female; D005334:Fever / Q000139:chemically induced; D006801:Humans; D007262:Infusions, Intravenous; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D017239:Paclitaxel / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D043823:Taxoids; D016896:Treatment Outcome; D014882:Water-Electrolyte Balance / Q000187:drug effects
chemical_list: D000932:Antiemetics; D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D003907:Dexamethasone; D017239:Paclitaxel